Abstract:Since 1985, we have tested several immunological approaches to suppressing HIV replication in HIV-infected patients and to prevent HIV acquisition in uninfected people. Here, after briefly reviewing our studies on immunosuppressive treatments and therapeutic dendritic cell-based therapies, we examine in more detail our work on the tolerogenic vaccines we developed against AIDS in Chinese macaques. The vaccine consisted of inactivated SIVmac239 particles adjuvanted with the Bacillus of Calmette and Guerin (BCG), Lactobacillus plantarum (LP), or Lactobacillus rhamnosus (LR). Without adjuvant, the vaccine administered by the intragastric route induced the usual simian immunodeficiency virus (SIV)-specific humoral immune responses but no post-challenge protection. In contrast, out of 24 macaques that were immunized with the adjuvanted vaccine and challenged intrarectally with SIVmac239 or SIVB670, 23 were sterilely protected for up to 5 years, while all control macaques were infected. On the other hand, all macaques of Indian origin that were immunized with the same adjuvanted vaccine were not protected. We then discovered that vaccinated Chinese macaques developed a previously unrecognized class of non-cytolytic MHC-Ib/E-restricted CD8+ T cells (or CD8+ T-Regs) that suppressed the activation of SIV RNA-infected CD4+ T cells and thereby inhibited the (activation-dependent) reverse transcription of the virus and prevented the establishment of SIV infection. Finally, we found a similar population of HLA-E-restricted CD8+ T-Regs in human elite controllers (a small group of HIV-infected patients whose viral replication is naturally inhibited). Ex vivo, their CD8+ T-Regs suppressed viral replication in the same manner as those of vaccinated Chinese macaques. It is noteworthy that all of these elite controllers had a homo- or heterozygous HLA-Bw4-80I genotype. Taking into account the longevity and the high percentage of vaccine-protected Chinese macaques together with the concomitant identification of a robust ex vivo correlate of protection and the discovery of similar CD8+ T-Regs in human elite controllers, preventive and therapeutic HIV vaccines should be envisaged in humans.

Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

A 30-year journey of trial and error towards a tolerogenic AIDS vaccine

CD8+ T cells in HIV control, cure and prevention

Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

Advanced Therapies for Human Immunodeficiency Virus

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

HIV Vaccines and Cure

Progress of HIV-specific CTL Responses among HIV-infected Individuals

Cross-Subtype Antibody and Cellular Immune Responses Induced by A Polyvalent Dna Prime-Protein Boost Hiv-1 Vaccine in Healthy Human Volunteers

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

HIV/AIDS vaccine development: are we walking out from the dark?

HIV vaccines induce CD8 + T cells with low antigen receptor sensitivity

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Understanding the Mechanisms and Limitations of Immune Control of HIV